caa a22 4500 445309385 CHVBK 20180317142624.0 cr unu---uuuuu 170323e20110701xx s 000 0 eng 10.1007/s00404-010-1609-8 doi (NATIONALLICENCE)springer-10.1007/s00404-010-1609-8 Quality of life and toxicity in breast cancer patients using adjuvant TAC (docetaxel, doxorubicin, cyclophosphamide), in comparison with FAC (doxorubicin, cyclophosphamide, 5-fluorouracil) [Elektronische Daten] [N. Hatam, N. Ahmadloo, A. Ahmad Kia Daliri, P. Bastani, M. Askarian] Objectives: The aim of this study was to compare two regimens of chemotherapy in patients with breast cancer, including FAC (doxorubicin, cyclophosphamide, and 5-fluorouracil) and TAC (docetaxel, doxorubicin and cyclophosphamide); and analyze the toxicity of these treatments and observe patient's health-related quality of life. Methods: Health-related quality of life was assessed for up to 4months (from the beginning to the end of chemotherapy cycles), using European organization and cancer treatment quality of life questionnaire (EORTC) QLQ-C30. A group of 100 patients, with node-positive breast cancer were studied in order to compare the toxicity of adjuvant therapy TAC with FAC and the subsequent effects on the patient's quality of life. Results: After a 4-month follow-up of patients, our findings showed that despite having the same mean score of QOL at the start of adjuvant chemotherapy, the QOL in TAC arm was decreased more as a result of the higher range of toxicity in TAC regimen. Conclusion: In spite of increase in disease-free patients who received TAC regimen and increase their survival rate, there is significant toxicity and decrease in QOL in TAC protocol compare to FAC protocol. Using prophylactic granulocyte colony stimulating factor (G-CSF) along with increased education aimed at improving patient's knowledge and also the provision of a supportive group involving psychiatrics and patients that have successfully experienced the same treatment may be helpful. Springer-Verlag, 2010 Quality of life nationallicence Toxicity nationallicence Adjuvant therapy nationallicence Breast cancer nationallicence Hatam N. School of Management and Medical Information Sciences, Shiraz University of Medical Science, Shiraz, Iran aut Ahmadloo N. Department of Radiation Oncology, Namazi Hospital, Shiraz University of Medical Science, Shiraz, Iran aut Ahmad Kia Daliri A. Division of the Health Economics, Center for Primary Health Care Research, Lund University, Lund, Sweden aut Bastani P. Shiraz University of Medical Science (SUMS), Shiraz, Iran aut Askarian M. Community Medicine Department, Shiraz University of Medical Science (SUMS), Shiraz, Iran aut Archives of Gynecology and Obstetrics Springer-Verlag 284/1(2011-07-01), 215-220 0932-0067 284:1<215 2011 284 404 https://doi.org/10.1007/s00404-010-1609-8 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s00404-010-1609-8 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Hatam N. School of Management and Medical Information Sciences, Shiraz University of Medical Science, Shiraz, Iran aut NATIONALLICENCE 700 1- Ahmadloo N. Department of Radiation Oncology, Namazi Hospital, Shiraz University of Medical Science, Shiraz, Iran aut NATIONALLICENCE 700 1- Ahmad Kia Daliri A. Division of the Health Economics, Center for Primary Health Care Research, Lund University, Lund, Sweden aut NATIONALLICENCE 700 1- Bastani P. Shiraz University of Medical Science (SUMS), Shiraz, Iran aut NATIONALLICENCE 700 1- Askarian M. Community Medicine Department, Shiraz University of Medical Science (SUMS), Shiraz, Iran aut NATIONALLICENCE 773 0- Archives of Gynecology and Obstetrics Springer-Verlag 284/1(2011-07-01), 215-220 0932-0067 284:1<215 2011 284 404 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer